BMO Capital Rates Taysha Gene Therapies (TSHA) buy

BMO Capital maintains a buy rating for Taysha Gene Therapies, setting a price target of $14, a 125.44% upside from the current price.

By EarningsIQ Research Desk · Published Jun 23, 2026, 11:01 AM EDT · Updated Jun 26, 2026, 9:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

BMO Capital rated Taysha Gene Therapies, Inc. ($TSHA) "buy" with a $14 price target on June 23, 2026.

Since the rating, $TSHA is down 0.7% after 1 week, down 15.0% after 1 month and down 47.2% to date (from the $6.86 close on Jun 23, 2026).

TSHA Taysha Gene Therapies, Inc.

$3.62 -31.05% year to date

Daily close · Oct 16, 2026

Key Points

BMO Capital reiterated its buy rating for Taysha Gene Therapies, Inc. on June 23, 2026, with a price target of $14.0.
The stock is currently trading at $6.21, which is significantly lower than BMO's target, suggesting a potential upside.
The consensus among analysts is a strong buy, with a mean price target of $13.0 from 13 opinions.

Get $TSHA trade alerts by text

We text you when insiders, Congress or big funds trade $TSHA. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Taysha Gene Therapies, Inc. alert may contain errors. Disclosures

BMO Capital's Continued Confidence

BMO Capital has reiterated its buy rating for Taysha Gene Therapies, Inc. (NASDAQ: TSHA) with a price target of $14.0. This action was taken on June 23, 2026, while the stock trades at $6.21. This target suggests that analysts see significant potential for the stock to rise as it is currently well below the target price.

Analyst rating track record

BMO Capital vs. the S&P 500

YTD return +8.83% hypothetical

All-time return +3.68% S&P 500 +26.13%

vs. S&P 500 -22.45% behind the index

Hypothetical returns from BMO Capital's disclosed trades, not real profit or advice. How we model this.

Analysts Set New Price Targets

BMO's recent rating aligns with several other firms that have expressed positive views on Taysha. Goldman Sachs maintains a buy rating with a target of $13.0, up from $11.0, indicating their growing confidence in the company. Needham also maintains a buy rating, setting their target at $12.0, while Baird holds an outperform rating with a price target of $15.0. These ratings reflect a strong consensus among analysts, with a recommendation key of strong buy from 13 analysts, and a mean price target of $13.0.

Stock Performance and Market Context

Currently trading at $6.21, Taysha Gene Therapies' stock is near its 52-week low of $2.87 and not far from its high of $7.30. This pricing context suggests that the stock has potential for recovery as analysts expect it to perform better in the future. The stock's current price is also above its 50-day moving average of $5.78, which can indicate positive momentum.

12-month forecast

$TSHA price target

Taysha Gene Therapies, Inc. daily closes and this analyst's $14 target. Not advice.

Recent Earnings

In its latest earnings report, Taysha Gene Therapies posted revenue of $5.49 million, but it reported a negative EPS of -$0.41. The company has not yet turned a profit, which is reflected in its forward P/E of -10.9. The next earnings report is scheduled for November 4, 2026, and investors will be looking for signs of improvement in both revenue and profitability.

What Taysha Gene Therapies, Inc. Does

Taysha Gene Therapies, Inc., based in Dallas, Texas, is a clinical-stage biotechnology company. It focuses on developing gene therapies for severe diseases affecting the central nervous system. Their work includes treatments for conditions like Rett syndrome and giant axonal neuropathy, making their future potential significant as they advance their therapies.

What’s Next for Taysha

As Taysha Gene Therapies approaches its next earnings date on November 4, 2026, investors will be keen to see how the company progresses with its clinical trials and revenue generation. The latest analyst ratings suggest a strong belief in the company’s future, but the upcoming earnings will provide more clarity on its financial health. Remember, the latest analyst actions reflect positions as of June 23, 2026, and may not represent current market conditions.